Description: DBV Technologies S.A. is engaged in the research, development, and marketing of products for the diagnosis and treatment of allergies, primarily food allergies in young children. The company provides Diallertest, a non-invasive patch allergy diagnostic for infants, children, or adults for the diagnosis of allergy in cow milk, wheat, and soybean. Its products include Viaskin Peanut, an immunotherapy product for the treatment of patients with peanut allergies; Viaskin Milk, for the treatment of CMPA and eosinophilic esophagitis, as well as food polyallergies; and Viaskin House Dust Mite, a mite desensitization product for the treatment of mite allergy. The company was founded in 2002 and is based in Bagneux, France.
Home Page: www.dbv-technologies.com
DBVT Technical Analysis
177-181 Avenue Pierre Brossolette
Montrouge,
92120
France
Phone:
33 1 55 42 78 78
Officers
| Name | Title |
|---|---|
| Mr. Daniel Tassé | CEO & Director |
| Mr. Sébastien Robitaille | Chief Financial Officer |
| Dr. Pharis Mohideen | Chief Medical Officer |
| Mr. Pascal Wotling | Chief Technical Operations Officer & Chief Quality Officer |
| Anne Pollak | Head of Investor Relations |
| Ms. Michele F. Robertson | Chief Legal Officer |
| Joseph Becker | VP of Global Corp. Communications |
| Ms. Caroline Daniere | Chief HR Officer & Chief of Staff |
| Dr. Wence Agbotounou | Chief Clinical Trial Officer & Sr. VP |
| Ms. Lucie Mondoulet | Sr. VP & Deputy CSO |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.356 |
| Price-to-Sales TTM: | 28.1487 |
| IPO Date: | 2014-10-22 |
| Fiscal Year End: | December |
| Full Time Employees: | 85 |